In 2025, the mosquito-borne infections testing market was valued at USD 1.3 billion. Based on Future Market Insights' analysis, demand for mosquito-borne infections testing is estimated to grow to USD 1.4 billion in 2026 and USD 2.1 billion by 2036. FMI projects a CAGR of 4.7% during the forecast period.
Absolute dollar growth of USD 0.8 billion over the decade signals steady incremental expansion driven by endemic region population growth and outbreak surveillance investments rather than transformational technology shifts. Despite public health funding volatility and pricing pressure in low-resource settings, major diagnostic manufacturers sustain profitability through high-volume rapid test sales and premium molecular diagnostic placements in reference laboratories.
As Peter Schultz, PhD, Chief Executive Officer of Calibr and Scripps Research, noted regarding the urgency of outbreak prevention, “Insect-borne infectious diseases remain primary causes of severe illnesses and fatalities worldwide, and new approaches to preventing outbreaks of these diseases are critically needed.” [1]
China (6.5% CAGR) and India (6.0% CAGR) drive new opportunities through expanding healthcare infrastructure and government surveillance programs. Brazil (5.0% CAGR) contributes via endemic disease burden and public health system investments. Mature testing markets such as Germany (5.5%), the United States (4.4%), the United Kingdom (3.9%), and Japan (3.4%) generate replacement demand through technology upgrades, with volume expansion constrained by low endemicity and reliance on travel-related testing.
Mosquito-borne infections testing comprises diagnostic assays and platforms designed to detect pathogens transmitted by mosquito vectors, including parasites (Plasmodium species causing malaria), viruses (dengue, Zika, chikungunya, West Nile, yellow fever), and associated immunological responses. These tests utilize molecular, serological, and rapid diagnostic technologies to identify active infections, support clinical management, enable outbreak surveillance, and guide public health interventions across endemic and non-endemic regions.
The report includes a comprehensive analysis of market dynamics, featuring Global and Regional Market Sizes (Volume and Value) and a 10-year Forecast (2026-2036). It covers segmental breakdowns by test type (Molecular Diagnostics, Immunoassay Systems, ELISA, Rapid Tests, Blot Systems, Microspot Array Diagnostics), indication (Malaria, Zika, Chikungunya, Dengue, Others), end user (Hospitals and Clinics, Private Commercial Laboratories, Academic and Research Centers), and geographic regions.
The scope excludes vector surveillance products not used for human diagnostics, insecticides and vector control products, and therapeutic pharmaceuticals for mosquito-borne infections. It also omits veterinary testing for animal arboviruses, focusing strictly on human diagnostic applications for mosquito-transmitted pathogens.
Based on FMI’s mosquito-borne infections testing market report, molecular diagnostics is estimated to hold a 28.0% share in 2026. The shift toward molecular methods is driven by the need for early detection during the viremic phase, where antibody tests often fail, pushing labs and frontline settings toward automated, high-throughput workflows and targeted multiplex capability.
Based on FMI’s mosquito-borne infections testing market report, malaria testing is estimated to hold a 35.0% share in 2026. While rapid tests provide the volume, value capture is shifting toward higher-information workflows and multiplexed kits that help differentiate co-endemic infections in clinically similar febrile presentations.
Future Market Insights analysis suggests that historical patterns point to a mature, public-health anchored diagnostics market where testing volume is structurally tied to seasonality, outbreak cycles, and government procurement rather than discretionary consumer demand. Estimated valuation in 2026 reflects an immediate "preparedness push" as health systems expand surveillance coverage and laboratory capacity to reduce time-to-detection and prevent downstream hospitalization costs during dengue, malaria, and other mosquito-borne outbreaks.
While rapid diagnostic tests continue to drive throughput, value growth increasingly comes from molecular and multiplex workflows that improve early-window detection and help clinicians differentiate co-endemic febrile illnesses. The forecast assumes a "new normal" where buyers prioritize total system reliability, data reporting, and supply continuity, with growth aligned to sustained vector control funding and routine screening programs.
Based on the regional analysis, mosquito-borne infections testing market is segmented into Africa, South Asia, Southeast Asia, Latin America, Europe, and North America across 40+ countries. The full report also offers market attractiveness analysis based on regional trends.
| Country | CAGR (2026 to 2036) |
|---|---|
| China | 6.5% |
| India | 6.0% |
| Germany | 5.5% |
| Brazil | 5.0% |
| United States | 4.4% |
| United Kingdom | 3.9% |
| Japan | 3.4% |
Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research
North America is characterized by travel medicine demand, imported case management, and rising alertness to localized transmission, which increases the need for rapid confirmation testing and public health surveillance support.
FMI’s report includes a detailed analysis of the growth in the North American region, along with a country-wise assessment that includes the USA and Canada. Readers can also find regional trends, regulations, and market growth based on different segments and countries in the North America region.
South Asia, led by India, is characterized by a dual-burden dynamic where endemic malaria coincides with increasingly severe seasonal dengue outbreaks, raising the value of differentiated kits that help clinicians and surveillance teams separate co-circulating febrile illnesses.
The full report analyze the mosquito-borne infections testing market across South Asia from 2021-2036, covering disease surveillance trends, testing adoption, and growth drivers in India and other South Asian countries. The assessment highlights trends that dictate test mix, procurement, and reporting practices.
Latin America is a critical market for arbovirus diagnostics, where dengue volume and re-emerging outbreaks increase decentralized testing needs across public health networks and local laboratories.
The report consists of a detailed analysis for the market in Brazil, Mexico, Argentina, Colombia, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as surveillance intensity, testing access, and public health procurement trends impacting growth in Latin America.
Europe is driven by travel-linked case management and high-tech surveillance, where testing demand concentrates around returning travelers, imported case monitoring, and public health lab confirmation workflows.
FMI’s analysis of the mosquito-borne infections testing market in Europe consists of country-wise assessment that includes Germany, the UK, France, Italy, Spain, Nordics, Benelux and Rest of Europe. Readers can know various surveillance practices, reporting structures, and evolving regional testing trends.
Market structure remains fragmented overall, yet practical competition is concentrated among a limited set of suppliers capable of meeting volume, regulatory, and operational expectations of national malaria programs, large hospital networks, and reference laboratories. A meaningful share of market value sits with manufacturers that can supply both rapid diagnostic tests and higher-complexity molecular workflows, while smaller players compete on single-disease kits with limited pricing leverage and higher demand volatility during non-outbreak periods. The primary competitive variable is not peak margin capture, but tender win-rate driven by proof of performance, quality consistency, and reliable delivery under surge conditions.
Producers with integrated manufacturing, validated quality systems, and multi-region regulatory clearances absorb raw material and logistics shocks more effectively and maintain continuity during outbreak spikes. Suppliers without scale rely on third-party manufacturing or constrained distribution, increasing exposure to stock-outs, batch variability, and requalification risk with public health buyers. Compliance capability further narrows the field. Ability to meet WHO-related procurement expectations, national regulatory requirements, and post-market surveillance obligations demands strong clinical evidence packages and traceable lot control, creating attrition among underinvested vendors.
Customer concentration reinforces buyer leverage. Large donors and ministries dual-source to avoid dependency, compressing pricing power and elevating service, training, connectivity, and reporting support as differentiators.
Recent Developments
The report includes full coverage of key trends from competitive benchmarking. Some of the recent developments covered in the reports:
| Metric | Value |
|---|---|
| Quantitative Units | USD 1.4 billion (2026) to USD 2.1 billion (2036), at a CAGR of 4.7% |
| Market Definition | The mosquito-borne infections testing market comprises diagnostic assays and platforms designed to detect mosquito-transmitted pathogens in human samples, including malaria parasites (Plasmodium species) and arboviruses such as dengue, Zika, chikungunya, West Nile, yellow fever, and Japanese encephalitis. Tests include molecular, serological, and rapid diagnostic technologies used for clinical diagnosis, treatment decisions, outbreak surveillance, and public health response across endemic and non-endemic regions. |
| Test Type Segmentation | Molecular Diagnostics, Immunoassay Systems, ELISA, Rapid Tests, Blot Systems and Evaluation Software, Microspot Array Diagnostics |
| Indication Segmentation | Malaria, Zika Virus, Chikungunya, Dengue, Others |
| End User Segmentation | Hospitals and Clinics, Private Commercial Laboratories, Academic and Research Centers, Others |
| Regions Covered | Africa, South Asia, Southeast Asia, Latin America, Europe, North America |
| Countries Covered | United States, Canada, Mexico, Brazil, Argentina, Germany, France, United Kingdom, Italy, Spain, China, India, Japan, South Korea, Vietnam, Thailand, Indonesia, Nigeria, Kenya and 40 plus countries |
| Key Companies Profiled | Abbott Laboratories, F. Hoffmann-La Roche Ltd., QIAGEN N.V., Thermo Fisher Scientific Inc., Cepheid (Danaher Corporation), bioMérieux SA, Siemens Healthineers AG, BD (Becton, Dickinson and Company), Bio-Rad Laboratories, Inc., DiaSorin S.p.A. |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid top-down and bottom-up market modeling validated through primary interviews with diagnostic manufacturers, reference laboratory directors, hospital infectious disease specialists, and public health officials, supported by WHO disease burden statistics, national surveillance reporting, and procurement and shipment benchmarking. |
How large is the demand for mosquito-borne infections testing in the global market in 2026?
Demand for mosquito-borne infections testing in the global market is estimated to be valued at USD 1.4 billion in 2026.
What will be the market size of mosquito-borne infections testing in the global market by 2036?
Market size for mosquito-borne infections testing is projected to reach USD 2.1 billion by 2036.
What is the expected demand growth for mosquito-borne infections testing in the global market between 2026 and 2036?
Demand for mosquito-borne infections testing in the global market is expected to grow at a CAGR of 4.7% between 2026 and 2036.
Which test type segment is poised to lead global sales by 2026?
Molecular diagnostics are expected to be the dominant test type, capturing approximately 28.0% of global market share in 2026 due to superior sensitivity and specificity enabling early detection and pathogen differentiation.
Which indication segment is projected to contribute significant share in the mosquito-borne infections testing market in 2026?
In terms of indication, the malaria segment is projected to command 35.0% share in the mosquito-borne infections testing market in 2026, driven by sustained high disease burden with 247 million annual cases and elimination program testing requirements.
What is driving mosquito-borne infections testing demand in China?
China's 6.5% CAGR is driven by expanding healthcare infrastructure, government surveillance programs for imported cases, and emerging autochthonous dengue transmission in southern provinces requiring enhanced diagnostic capacity.
What compliance standards are referenced for China?
China's NMPA medical device registration requirements and national surveillance reporting standards are referenced as key compliance benchmarks.
What is the United States growth outlook in this report?
The United States is projected to grow at a CAGR of 4.4% during 2026 to 2036, supported by CDC ArboNET surveillance system requirements, travel medicine practice demand, and emerging local transmission monitoring.
Why is Germany's growth rate significant in this report?
Germany's 5.5% CAGR reflects increasing travel to endemic regions, emerging autochthonous transmission in Southern Europe requiring surveillance, and strong public health laboratory capacity.
What type of demand dominates in endemic regions?
Volume demand through public health procurement for malaria rapid diagnostic tests and outbreak response testing dominates endemic regions, with pricing pressure from donor-funded mechanisms.
What is Japan's growth outlook in this report?
Japan is projected to grow at a CAGR of 3.4% during 2026 to 2036, characterized by imported case testing for travelers and expatriates returning from endemic regions.
Does the report cover Australia in its regional analysis?
Australia is included within Oceania under the regional coverage framework, recognizing its imported case testing requirements and emerging local transmission risk in northern Queensland.
What are the sources referred to for analyzing the market in Africa?
WHO Global Malaria Programme reports, The Global Fund procurement data, and national malaria control program statistics are cited as primary reference sources.
What is the main demand theme linked to Southeast Asia coverage?
Southeast Asia demand centers on high dengue burden, seasonal outbreak response requirements, and tourism sector travel medicine testing.
Which end-user segment is strategically important for volume growth?
Hospitals and clinics remain the dominant end-user segment at approximately 40% market share, serving as first point of care for symptomatic patients and outbreak surveillance reporting hubs.
What are mosquito-borne infections tests and what are they mainly used for?
Mosquito-borne infections tests are diagnostic assays detecting pathogens transmitted by mosquitoes, primarily used for clinical diagnosis of malaria, dengue, Zika, and chikungunya, and for public health surveillance and outbreak monitoring.
What does the mosquito-borne infections testing market mean in this report?
The mosquito-borne infections testing market refers to global production and supply of diagnostic assays and platforms for detecting mosquito-transmitted pathogens in human samples for clinical and surveillance applications.
What is included in the scope of this mosquito-borne infections testing market report?
Scope covers mosquito-borne infections testing by test type (molecular diagnostics, rapid tests, immunoassays), indication (malaria, dengue, Zika, chikungunya), end user (hospitals, laboratories), and geographic regions.
What is excluded from the scope of this report?
Vector surveillance products, insecticides, therapeutic pharmaceuticals, and veterinary testing are excluded.
What does market forecast mean on this page?
Market forecast represents a model-based projection built on defined assumptions for strategic planning purposes.
How does FMI build and validate the mosquito-borne infections testing market forecast?
Forecast is developed using hybrid top-down and bottom-up modeling validated through WHO disease burden data, national testing volume statistics, and manufacturer shipment records.
What does zero reliance on speculative third-party market research mean here?
Primary interviews and verifiable public datasets including WHO procurement data, national surveillance reports, and corporate financial filings are used instead of unverified syndicated market estimates.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Mosquito-borne infections Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
